The αDBS® platform represents a significant departure from conventional deep brain stimulation, which typically relies on fixed stimulation levels regardless of a patient's fluctuating brain states throughout the day. By utilizing a patented Adaptive Therapy Stim Engine, the device senses local field potentials and keeps the patient within an optimal therapeutic window. This development is supported by the integration of WebBioBank™, a cloud-based infrastructure that aggregates de-identified neural data to help clinicians refine long-term treatment strategies.

Following two decades of research, this certification allows the company to deploy its connected care model commercially. The system includes an implantable pulse generator, a physician interface, and a patient remote for data collection. While the European market now has access to the technology, the company continues its global expansion efforts through the ADVENT pivotal trial, which holds an Investigational Device Exemption from the U.S. FDA to evaluate the system for Parkinson’s disease treatment.